These agents work by blocking specific proteins on immune cells, such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which cancer cells exploit to evade immune detection. The gene discussed is CTLA4; the disease is cancer.